Gland Pharma Ltd - 543245 - Board Meeting Outcome for Outcome Of The Board Meeting
The Board of Directors at its meeting held on May 19, 2022 has inter-alia approved the Audited financial results of the Company for the quarter and financial year ended March 31, 2022. The 44th Annual General Meeting of the members of the Company will be held through video conferencing (VC)/ other audio-visual means (OAVM) on Tuesday, August 30, 2022. Gland Pharma Ltd - 543245 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended March 31, 2022 Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q4FY22 Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Launch of Bortezomib for Injection through our partner in the US Market Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 2,73,800 Equity shares under ESOP Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the Quarter ending March 31, 2022 Gland Pharma Ltd - 543245 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGland Pharma Ltd 2CINL24239TG1978PLC002276 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: P Sampath Kumar Designation: Company Secretary and Compliance Officer EmailId: sampath@glandpharma.com Name of the Chief Financial Officer: Ravi Shekhar Mitra Designation: Chief Financial Officer EmailId: ravi.mitra@glandpharma.com Date: 27/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nicomac Machinery Pvt Ltd Gland Pharma Ltd - 543245 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Gland Pharma Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here